Cargando…
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407567/ https://www.ncbi.nlm.nih.gov/pubmed/32629964 http://dx.doi.org/10.3390/cancers12071744 |
_version_ | 1783567652509188096 |
---|---|
author | Lyons Rimmer, Jade Ercolano, Emanuela Baiz, Daniele Makhija, Mahindra Berger, Allison Sells, Todd Stroud, Steve Hilton, David Adams, Claire L. Hanemann, C Oliver |
author_facet | Lyons Rimmer, Jade Ercolano, Emanuela Baiz, Daniele Makhija, Mahindra Berger, Allison Sells, Todd Stroud, Steve Hilton, David Adams, Claire L. Hanemann, C Oliver |
author_sort | Lyons Rimmer, Jade |
collection | PubMed |
description | Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase suppressor of Ras 1 (KSR1) are upregulated in Merlin-deficient tumours, which drives tumour growth. Identifying small molecules that inhibit these key pathways may provide an effective treatment option for patients with meningioma. We used meningioma tissue and primary cells derived from meningioma tumours to investigate the expression of DDB1 and Cullin 4-associated factor 1 (DCAF1) and KSR1, and confirmed these proteins were overexpressed. We then used primary cells to assess the therapeutic potential of MLN3651, a neddylation inhibitor which impacts the activity of the CRL family of E3 ubiquitin ligases and the MAPK/ERK kinase (MEK1/2) inhibitor selumetinib. MLN3651 treatment reduced proliferation and activated apoptosis, whilst increasing Raf/MEK/ERK pathway activation. The combination of MLN3651 and the MEK1/2 inhibitor selumetinib prevented the increase in Raf/MEK/ERK activity, and had an additive effect compared with either treatment alone. Therefore, the combined targeting of CRL4-DCAF1 and Raf/MEK/ERK activity represents an attractive novel strategy in the treatment of Merlin-deficient meningioma. |
format | Online Article Text |
id | pubmed-7407567 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74075672020-08-25 The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma Lyons Rimmer, Jade Ercolano, Emanuela Baiz, Daniele Makhija, Mahindra Berger, Allison Sells, Todd Stroud, Steve Hilton, David Adams, Claire L. Hanemann, C Oliver Cancers (Basel) Article Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase suppressor of Ras 1 (KSR1) are upregulated in Merlin-deficient tumours, which drives tumour growth. Identifying small molecules that inhibit these key pathways may provide an effective treatment option for patients with meningioma. We used meningioma tissue and primary cells derived from meningioma tumours to investigate the expression of DDB1 and Cullin 4-associated factor 1 (DCAF1) and KSR1, and confirmed these proteins were overexpressed. We then used primary cells to assess the therapeutic potential of MLN3651, a neddylation inhibitor which impacts the activity of the CRL family of E3 ubiquitin ligases and the MAPK/ERK kinase (MEK1/2) inhibitor selumetinib. MLN3651 treatment reduced proliferation and activated apoptosis, whilst increasing Raf/MEK/ERK pathway activation. The combination of MLN3651 and the MEK1/2 inhibitor selumetinib prevented the increase in Raf/MEK/ERK activity, and had an additive effect compared with either treatment alone. Therefore, the combined targeting of CRL4-DCAF1 and Raf/MEK/ERK activity represents an attractive novel strategy in the treatment of Merlin-deficient meningioma. MDPI 2020-06-30 /pmc/articles/PMC7407567/ /pubmed/32629964 http://dx.doi.org/10.3390/cancers12071744 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lyons Rimmer, Jade Ercolano, Emanuela Baiz, Daniele Makhija, Mahindra Berger, Allison Sells, Todd Stroud, Steve Hilton, David Adams, Claire L. Hanemann, C Oliver The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title_full | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title_fullStr | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title_full_unstemmed | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title_short | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma |
title_sort | potential of mln3651 in combination with selumetinib as a treatment for merlin-deficient meningioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407567/ https://www.ncbi.nlm.nih.gov/pubmed/32629964 http://dx.doi.org/10.3390/cancers12071744 |
work_keys_str_mv | AT lyonsrimmerjade thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT ercolanoemanuela thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT baizdaniele thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT makhijamahindra thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT bergerallison thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT sellstodd thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT stroudsteve thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT hiltondavid thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT adamsclairel thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT hanemanncoliver thepotentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT lyonsrimmerjade potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT ercolanoemanuela potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT baizdaniele potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT makhijamahindra potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT bergerallison potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT sellstodd potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT stroudsteve potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT hiltondavid potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT adamsclairel potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma AT hanemanncoliver potentialofmln3651incombinationwithselumetinibasatreatmentformerlindeficientmeningioma |